QA102 Phase 1 Study in Healthy Young and Older Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

May 17, 2021

Primary Completion Date

November 15, 2021

Study Completion Date

November 15, 2021

Conditions
Age-related Macular Degeneration
Interventions
DRUG

QA102

"Intervention of Part 1: 6 dose levels (50mg, 100mg, 200mg, 400mg, 800mg, 1600mg of QA102 capsules), oral administration, single dose.~Intervention of Part 2: 2 dose levels (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 1 of the study), oral administration.~Intervention of Part 3: 1 dose level (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 2 of the study), oral administration."

DRUG

Placebo

"Intervention of Part 1: 6 dose levels (50mg, 100mg, 200mg, 400mg, 800mg, 1600mg of Placebo capsules), oral administration, single dose.~Intervention of Part 2: 2 dose levels (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 1 of the study), oral administration.~Intervention of Part 3: 1 dose level (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 2 of the study), oral administration."

Trial Locations (1)

53704

Covance Clinical Research Unit Inc., Madison

All Listed Sponsors
lead

Smilebiotek Zhuhai Limited

INDUSTRY